Weekly Analysts’ Ratings Updates for Amgen (AMGN)

Amgen (NASDAQ: AMGN) has recently received a number of price target changes and ratings updates:

• 12/22/2025 – Amgen had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Amgen had its “buy (b)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Amgen was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 12/12/2025 – Amgen had its price target lowered by analysts at Morgan Stanley from $329.00 to $304.00. They now have an “equal weight” rating on the stock.
• 12/10/2025 – Amgen had its “buy” rating reaffirmed by analysts at HSBC Holdings plc. They now have a $425.00 price target on the stock.
• 12/10/2025 – Amgen had its price target raised by analysts at Wells Fargo & Company from $300.00 to $325.00. They now have an “equal weight” rating on the stock.
• 12/7/2025 – Amgen was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 12/5/2025 – Amgen was upgraded by analysts at Erste Group Bank AG from a “hold” rating to a “buy” rating.
• 12/3/2025 – Amgen had its price target raised by analysts at BMO Capital Markets from $335.00 to $372.00. They now have an “outperform” rating on the stock.
• 11/29/2025 – Amgen was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/25/2025 – Amgen was given a new $400.00 price target on by analysts at Wells Fargo & Company.
• 11/25/2025 – Amgen had its “buy” rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
• 11/24/2025 – Amgen is now covered by analysts at Truist Financial Corporation. They set a “hold” rating and a $318.00 price target on the stock.
• 11/19/2025 – Amgen had its price target raised by analysts at HSBC Holdings plc from $343.00 to $381.00. They now have a “buy” rating on the stock.
• 11/18/2025 – Amgen had its price target raised by analysts at Daiwa Capital Markets from $310.00 to $370.00. They now have an “outperform” rating on the stock.
• 11/14/2025 – Amgen had its price target raised by analysts at Piper Sandler from $342.00 to $381.00. They now have an “overweight” rating on the stock.
• 11/13/2025 – Amgen is now covered by analysts at Scotiabank. They set a “sector outperform” rating and a $385.00 price target on the stock.
• 11/12/2025 – Amgen was upgraded by analysts at Scotiabank to a “strong-buy” rating.
• 11/11/2025 – Amgen had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $280.00 to $285.00. They now have a “hold” rating on the stock.
• 11/10/2025 – Amgen had its price target raised by analysts at DZ Bank AG from $335.00 to $364.00.
• 11/8/2025 – Amgen was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/6/2025 – Amgen had its price target raised by analysts at Cantor Fitzgerald from $305.00 to $315.00. They now have a “neutral” rating on the stock.
• 11/6/2025 – Amgen had its price target raised by analysts at Guggenheim from $288.00 to $305.00. They now have a “neutral” rating on the stock.
• 11/5/2025 – Amgen had its “overweight” rating reaffirmed by analysts at Piper Sandler.
• 11/5/2025 – Amgen had its price target raised by analysts at Wells Fargo & Company from $280.00 to $300.00. They now have an “overweight” rating on the stock.
• 11/5/2025 – Amgen had its price target lowered by analysts at Morgan Stanley from $333.00 to $329.00. They now have an “equal weight” rating on the stock.
• 11/5/2025 – Amgen had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $405.00 to $400.00. They now have a “buy” rating on the stock.
• 10/27/2025 – Amgen was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. Amgen’s dividend payout ratio (DPR) is presently 77.90%.

Insider Buying and Selling

In related news, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the sale, the executive vice president owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. This represents a 14.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the transaction, the senior vice president directly owned 7,082 shares in the company, valued at $2,381,251.68. This trade represents a 11.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 10,908 shares of company stock worth $3,674,966. 0.76% of the stock is owned by insiders.

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.